Compare ESCA & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESCA | SGHT |
|---|---|---|
| Founded | 1922 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.8M | 235.0M |
| IPO Year | 1995 | 2021 |
| Metric | ESCA | SGHT |
|---|---|---|
| Price | $19.63 | $4.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 29.7K | ★ 298.9K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.50% | N/A |
| EPS Growth | 6.45 | ★ 28.16 |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $180,541,000.00 | $77,363,000.00 |
| Revenue This Year | $4.15 | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $61.19 | ★ N/A |
| Revenue Growth | ★ 2.71 | N/A |
| 52 Week Low | $11.41 | $2.81 |
| 52 Week High | $21.20 | $9.24 |
| Indicator | ESCA | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 61.94 | 55.08 |
| Support Level | $12.22 | $3.29 |
| Resistance Level | N/A | $5.25 |
| Average True Range (ATR) | 0.94 | 0.30 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 58.60 | 38.41 |
Escalade Inc manufactures and distributes sporting goods for a varied range of activities. These sports include archery, table tennis, basketball goals, trampoline, play systems, fitness, game tables like hockey and soccer, billiards, darting, and other outdoor games. These products are sold under the brand names like Goalrilla, Goalsetter, Woodplay, Silverback, Nodor, Rage, Child Life, among others. The geographic segments in which the company operates are the United States, Canada, Australia, and Other regions.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.